IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.961
AS - Asia 2.417
EU - Europa 2.216
SA - Sud America 253
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 20
Totale 9.944
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.705
SG - Singapore 1.599
IT - Italia 997
CN - Cina 380
SE - Svezia 313
GB - Regno Unito 301
DE - Germania 250
CA - Canada 216
BR - Brasile 210
IN - India 132
FI - Finlandia 88
HK - Hong Kong 52
NL - Olanda 48
ES - Italia 29
BD - Bangladesh 28
FR - Francia 26
PK - Pakistan 26
RU - Federazione Russa 26
JO - Giordania 24
RO - Romania 24
UA - Ucraina 24
ZA - Sudafrica 24
MX - Messico 23
EU - Europa 22
JP - Giappone 21
IQ - Iraq 20
ID - Indonesia 18
VN - Vietnam 18
PL - Polonia 17
TR - Turchia 17
IR - Iran 16
SA - Arabia Saudita 16
AU - Australia 15
AT - Austria 13
CZ - Repubblica Ceca 13
CO - Colombia 11
LT - Lituania 10
PT - Portogallo 9
CL - Cile 8
EE - Estonia 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
MY - Malesia 7
EC - Ecuador 6
ET - Etiopia 6
IE - Irlanda 6
MA - Marocco 6
NG - Nigeria 6
VE - Venezuela 6
AR - Argentina 5
LB - Libano 5
CU - Cuba 4
CY - Cipro 4
KR - Corea 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TW - Taiwan 4
BG - Bulgaria 3
GT - Guatemala 3
HN - Honduras 3
IL - Israele 3
LK - Sri Lanka 3
PE - Perù 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CH - Svizzera 2
HR - Croazia 2
HU - Ungheria 2
KE - Kenya 2
PS - Palestinian Territory 2
PY - Paraguay 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
JM - Giamaica 1
KI - Kiribati 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TL - Timor Orientale 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 9.944
Salva come PNG Salva come JPEG
Città #
Chandler 807
Singapore 652
Santa Clara 406
Milan 352
Lawrence 343
Princeton 343
Chicago 243
London 213
Munich 198
Wilmington 185
Ottawa 160
Ashburn 155
Des Moines 115
Catanzaro 105
Turku 65
Boardman 60
Beijing 51
Los Angeles 47
Shanghai 43
Hong Kong 42
Rome 35
Norwalk 34
Pune 34
Guangzhou 30
New York 30
Council Bluffs 28
Redmond 27
San Francisco 26
São Paulo 26
Brooklyn 24
The Dalles 24
Helsinki 23
Naples 23
Redwood City 21
Dallas 19
Warsaw 18
Montreal 17
Amman 16
Parma 16
San Nicola Manfredi 16
Shenzhen 16
Columbus 15
Manchester 15
Stockholm 14
Chennai 13
Seattle 13
Tokyo 13
Atlanta 12
Augusta 12
Carbonia 12
Cosenza 12
Horia 12
Palermo 12
Phoenix 12
Reggio Calabria 12
Spezzano della Sila 12
Toronto 12
Hanover 11
Johannesburg 11
Mountain View 11
Olomouc 11
Delhi 10
Rio de Janeiro 10
West Jordan 10
Amsterdam 9
Boston 9
Jiaxing 9
Afragola 8
Ankara 8
Denver 8
Ercolano 8
Ho Chi Minh City 8
Irbid 8
Madrid 8
Mexico City 8
Santo Stefano di Rogliano 8
Washington 8
Baghdad 7
Charlotte 7
Jeddah 7
Kaunas 7
Las Vegas 7
Leawood 7
Ovada 7
Rogliano 7
Secaucus 7
Settingiano 7
Aversa 6
Cape Town 6
Catania 6
Dhaka 6
Hanoi 6
Melito di Porto Salvo 6
Moscow 6
Nanjing 6
Paris 6
Riyadh 6
Timisoara 6
Wuxi 6
Xi'an 6
Totale 5.620
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 370
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 87
miR-22 suppresses DNA ligase III addiction in multiple myeloma 85
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 83
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 70
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 66
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 63
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 62
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 60
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 59
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 56
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 55
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 54
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 54
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 52
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 49
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 49
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 49
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 48
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 48
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 48
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 47
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 47
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 47
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 46
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 45
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 45
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 45
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 45
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 45
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 44
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 44
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 43
Mir-34: a new weapon against cancer? 43
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 43
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 43
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 42
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 41
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 41
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 41
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 40
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 40
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 40
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 40
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 40
Mir-221/222 are promising targets for innovative anticancer therapy 39
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 39
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 39
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 39
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 39
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 39
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 39
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 38
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 38
A PH-DEPENDENT DIFFERENTIAL CYTO-TOXICITY OF OUABAIN FOR HUMAN-CELLS TRANSFORMED BY CERTAIN ONCOGENES 38
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 38
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 38
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 38
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 38
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 38
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 38
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 38
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 37
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 37
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 37
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 37
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 37
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 37
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 37
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 37
Mmrf-commpass data integration and analysis for identifying prognostic markers 37
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 37
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 36
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 36
REVERSAL OF ADRIAMYCIN RESISTANCE BY RECOMBINANT ALPHA-INTERFERON IN MULTIDRUG-RESISTANT HUMAN COLON-CARCINOMA LOVO-DOXORUBICIN CELLS 36
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 36
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 36
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 36
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 36
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 36
Integration of DNA Microarray with Clinical and Genomic Data 36
Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment 35
SITE-SELECTIVE CAMP ANALOGS AT MICROMOLAR CONCENTRATIONS INDUCE GROWTH ARREST AND DIFFERENTIATION OF ACUTE PROMYELOCYTIC, CHRONIC MYELOCYTIC, AND ACUTE LYMPHOCYTIC HUMAN-LEUKEMIA CELL-LINES 35
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 35
miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. 34
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 34
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 33
Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma 33
8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor 33
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 33
Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone 33
miR-221/222 inhibitors for the treatment of multiple myeloma 33
DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine 33
Effects of transforming growth factor-β and budesonide on mitogen-activated protein kinase activation and apoptosis in airway epithelial cells 33
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 32
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. 32
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways 32
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 32
Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: Experimental models and translational issues 32
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications 32
Totale 4.580
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.393
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021324 0 4 10 18 45 31 33 16 48 69 44 6
2021/2022952 17 6 12 278 50 19 31 197 95 91 144 12
2022/20232.556 706 75 83 206 274 227 13 161 387 160 214 50
2023/20241.353 310 134 115 93 94 320 40 53 15 46 61 72
2024/20254.071 551 241 183 127 225 512 108 153 477 247 415 832
2025/2026642 406 236 0 0 0 0 0 0 0 0 0 0
Totale 10.227